CD274 and cancer: Exploring the impact of anti-cancer treatments on PD-L1 expression and on the regulation of its subcellular localization is particularly important as, when over-expressed on plasma-membrane, it can be targeted by therapeutic antibodies such as atezolizumab, avelumab or durvalumab, to improve the outcome of anti-cancer therapies.